JP2025516683A - Ｔｙｋ２阻害剤の結晶形態およびその使用 - Google Patents

Ｔｙｋ２阻害剤の結晶形態およびその使用 Download PDF

Info

Publication number
JP2025516683A
JP2025516683A JP2024566809A JP2024566809A JP2025516683A JP 2025516683 A JP2025516683 A JP 2025516683A JP 2024566809 A JP2024566809 A JP 2024566809A JP 2024566809 A JP2024566809 A JP 2024566809A JP 2025516683 A JP2025516683 A JP 2025516683A
Authority
JP
Japan
Prior art keywords
crystalline form
diffraction pattern
degrees
powder
characteristic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024566809A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025516683A5 (enExample
Inventor
バイ，コルボット
レマーチュク，トラビス
Original Assignee
アルミス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルミス インコーポレイテッド filed Critical アルミス インコーポレイテッド
Publication of JP2025516683A publication Critical patent/JP2025516683A/ja
Publication of JP2025516683A5 publication Critical patent/JP2025516683A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024566809A 2022-05-13 2023-05-12 Ｔｙｋ２阻害剤の結晶形態およびその使用 Pending JP2025516683A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263341528P 2022-05-13 2022-05-13
US63/341,528 2022-05-13
US202263405577P 2022-09-12 2022-09-12
US63/405,577 2022-09-12
PCT/US2023/021986 WO2023220338A1 (en) 2022-05-13 2023-05-12 Crystalline forms of a tyk2 inhibitor and uses thereof

Publications (2)

Publication Number Publication Date
JP2025516683A true JP2025516683A (ja) 2025-05-30
JP2025516683A5 JP2025516683A5 (enExample) 2026-05-18

Family

ID=86760338

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024566809A Pending JP2025516683A (ja) 2022-05-13 2023-05-12 Ｔｙｋ２阻害剤の結晶形態およびその使用

Country Status (11)

Country Link
EP (1) EP4522602A1 (enExample)
JP (1) JP2025516683A (enExample)
KR (1) KR20250009492A (enExample)
CN (1) CN119907791A (enExample)
AU (1) AU2023269081A1 (enExample)
CA (1) CA3253365A1 (enExample)
CL (1) CL2024003456A1 (enExample)
IL (1) IL317011A (enExample)
MX (1) MX2024014000A (enExample)
TW (1) TW202409007A (enExample)
WO (1) WO2023220338A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202428571A (zh) * 2022-10-10 2024-07-16 美商雅盧米斯公司 Tyk2抑制劑之晶型及其用途
WO2026019902A1 (en) * 2024-07-16 2026-01-22 Alumis Inc. Crystalline forms of a tyk2 inhibitor and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20250048T1 (hr) * 2018-10-22 2025-03-28 Alumis Inc. Inhibitori tyk2 i njihova uporaba

Also Published As

Publication number Publication date
KR20250009492A (ko) 2025-01-17
CA3253365A1 (en) 2023-11-16
CL2024003456A1 (es) 2025-04-25
AU2023269081A1 (en) 2024-11-28
CN119907791A (zh) 2025-04-29
TW202409007A (zh) 2024-03-01
WO2023220338A1 (en) 2023-11-16
EP4522602A1 (en) 2025-03-19
MX2024014000A (es) 2025-02-10
IL317011A (en) 2025-01-01

Similar Documents

Publication Publication Date Title
AU2020220512B2 (en) FGFR inhibitor compound in solid form and preparation method therefor
EP3216790B1 (en) Crystalline form of jak kinase inhibitor bisulfate and a preparation method thereof
NO341930B1 (no) Krystallinske former for 4-metyl-N-[3-(4-metylimidazol-1-yl)-5-trifluormetylfenyl]-3-(4-pyridin-3-ylpyrimidin-2-ylamino)benzamid
CN110678178B (zh) Mk2抑制剂的形式和组合物
KR20250009492A (ko) Tyk2 억제제의 결정질 형태 및 그의 용도
JP2025532561A (ja) Ｔｙｋ２阻害剤の結晶形態およびその使用
EP4212534A1 (en) Salt of compound for degrading btk, crystal form thereof, and use thereof in medicine
EP3271351A1 (en) Novel polymorphic form x of nilotinib dihydrochloride hydrate
US20260138965A1 (en) Crystalline forms of a tyk2 inhibitor and uses thereof
US20240368185A1 (en) Macrocyclic azolopyridines
WO2026019900A1 (en) Crystalline forms of a tyk2 inhibitor and uses thereof
EP4602040A1 (en) Crystalline forms of a tyk2 inhibitor and uses thereof
WO2026019902A1 (en) Crystalline forms of a tyk2 inhibitor and uses thereof
WO2026019908A1 (en) Crystalline forms of a tyk2 inhibitor and uses thereof
TW201815762A (zh) 經尿素及苯基取代之６員環狀胺或內醯胺
TW202610624A (zh) Tyk2抑制劑之晶型及其用途
TW202610625A (zh) Tyk2抑制劑之晶型及其用途
AU2014231863A1 (en) Salt of pyrrolidin-3-yl acetic acid derivative and crystals thereof
CN110903291B (zh) 一种杂芳基并[4,3-c]嘧啶-5-胺类衍生物的盐、盐的晶型及制备方法
JP2025509759A (ja) レボドーパチロシンの多形
HK40088675A (en) Salt of compound for degrading btk, crystal form thereof, and use thereof in medicine
JP2023524622A (ja) ６－クロロ－７－（４－（４－クロロベンジル）ピペラジン－１－イル）－２－（１，３－ジメチル－１Ｈ－ピラゾール－４－イル）－３Ｈ－イミダゾ［４，５－ｂ］ピリジンの塩及び多形体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260508

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260508